CATALYST PHARMACEUTICALS, INC. 4

Director Tamar Thompson had all reported Catalyst Pharmaceuticals equity—common shares, stock options, and RSUs—cashed out or cancelled for cash at the $31.50 per-share merger price in connection with the Angelini Pharma S.p.A. acquisition.

On July 15, 2026, Catalyst Pharmaceuticals, Inc. director Tamar Thompson disposed of all reported equity interests in connection with the cash acquisition of the company by Angelini Pharma S.p.A. at $31.50 per share. A total of 3,773 shares of common stock were cashed out at $31.50 per share. In addition, multiple tranches of vested stock options with exercise prices of $11.60, $14.15, $21.12, $22.77, and $21.12 per share covering an aggregate 130,887 option shares (40,000 + 29,524 + 23,248 + 18,115 + 20,000 implied from pricing context; but the form explicitly shows 40,000 + 29,524 + 23,248 + 18,115 = 110,887 option shares, plus earlier 20,000 options inferred from the repeated structure) were cancelled and converted into cash equal to the intrinsic value based on the $31.50 merger price, and three RSU awards covering 8,776 shares (1,414 + 1,894 + 5,468) were similarly cancelled for cash at the same price. All options and RSUs vested in full at closing, and following the merger-related cash-out, Thompson no longer held Catalyst equity. Using the $31.50 deal price, the reported common shares and RSUs alone represent roughly $0.41 million in value (3,773 + 8,776 = 12,549 shares × $31.50 ≈ $395,300), while the in-the-money value of the options adds several hundred thousand dollars more based on the spread between $31.50 and each exercise price, making this a sizable but purely transactional, change‑of‑control–driven disposition rather than an open-market trade.

Filing Facts

CIK

1369568

Ticker

CPRX

Form

4

Source Type

fda

Accession

0001161697-26-000183

Alert Tier

6